{
  "event_id": "a1f72b63eb1a",
  "ticker": "LLY",
  "company_name": "Eli Lilly",
  "drug_name": "Kisunla donanemab-azbt",
  "pdufa_date": "20240702",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:TRAILBLAZER-ALZ 2 Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.738583",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Alzheimer's disease",
    "source": "websearch:TRAILBLAZER-ALZ 2 Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.738585",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "donanemab-azbt",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T07:18:32.440880",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Neurology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.867945",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T07:18:32.440880",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:TRAILBLAZER-ALZ 2 Phase 3",
    "confidence": 0.95,
    "evidence": [
      "TRAILBLAZER-ALZ 2 Phase 3"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.738569",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "<0.0001",
    "source": "websearch:TRAILBLAZER-ALZ 2 Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.738577",
    "error": null
  },
  "p_value_numeric": 0.0001,
  "effect_size": {
    "status": "found",
    "value": "35% slowing of cognitive decline on iADRS; 36% on CDR-SB",
    "source": "websearch:TRAILBLAZER-ALZ 2 Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:07:20.738579",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": true,
    "source": "known_safety_database",
    "confidence": 0.95,
    "tier": 1,
    "reason": "ARIA risk",
    "severity": "medium"
  },
  "phase3_study_names": [
    "Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease"
  ],
  "nct_ids": [
    "NCT03367403"
  ],
  "enrollment": {
    "count": 272,
    "type": "ACTUAL",
    "nct_id": "NCT03367403",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:28:10.496920"
  },
  "has_prior_crl": {
    "status": "found",
    "value": true,
    "source": "derived_from_resubmission",
    "confidence": 0.85,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": true,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:24:16.221048",
  "enriched_at": "2026-01-11T19:20:23.102164",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "7cd71f4f97c8",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": false,
    "accelerated_approval": false
  },
  "mechanism_of_action": "Anti-amyloid antibody",
  "adcom_info": {
    "scheduled": true,
    "held": true,
    "outcome": "favorable",
    "vote": "positive"
  },
  "days_to_pdufa": -557,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:40.459333",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:40:41.097986"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:40:41.097996"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA approves Kisunlaâ„¢ (donanemab-azbt) for Alzheimer's ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:20:06.901583",
    "search_status": "FOUND"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:20:11.792464",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Approves Donanemab (Kisunla) For Early Symptomatic ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:20:15.405915",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Approves Donanemab (Kisunla) For Early Symptomatic ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:20:16.478931",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:20:23.102147",
    "search_status": "CONFIRMED_NONE"
  }
}